Literature DB >> 25936414

Neonatal hyperthermia and thermal stress in low- and middle-income countries: a hidden cause of death in extremely low-birthweight neonates.

Hippolite O Amadi, Eyinade K Olateju, Peter Alabi, Mohammed B Kawuwa, Mike O Ibadin, Akin O Osibogun.   

Abstract

BACKGROUND: Over 70% of neonatal deaths in Nigeria occur within the first 7 days of life and, despite the millennium development goals, there has been no significant reduction of this figure.
OBJECTIVE: To investigate how rapid changes of temperature outside the physiologically allowable range in extremely low-birthweight infants are associated with increased mortality.
METHODS: Ninety-eight neonatal cases in three Nigerian tertiary-care hospitals were retrospectively recruited; on the basis of birthweight  < 1500 g, this number was reduced to 41 for a two-stage analysis. In the first stage, 34 cases recruited over 24 months were analysed. In the second stage, seven cases recruited over 6 months were analysed; these were neonates managed with a new temperature control technique (the 'handy approach') to enable comparison of outcomes. The mean (SD) birthweight of the infants analysed was 991 g (251), and 28 of them were of extremely low-birthweight (ELBW) [mean (SD) 846 g (128)]. A lifetime temperature plot with a clearly visible reference zone was developed, from which all thermal stresses and their duration associated with mortality were identified and defined on the basis of their characteristics. Methods of quantifying the magnitude and duration of these thermal stresses were devised to enable definition of critical values. This was then applied to calculate a measure of the various thermal stresses which may have contributed to neonatal death.
RESULTS: Hypothermic events were very common in all the infants in the study period, but were not significantly associated with mortality. However, hyperthermic events occurred in 35% of the infants and were more likely to be associated with mortality. Most neonates with prolonged hypothermia culminating in rapid hyperthermia survived. However, all ELBW neonates who experienced prolonged hyperthermia culminating in rapid hypothermia died within 8 hours of the event. There was greater ELBW survival (6/6) in the second stage using the 'handy approach' than in the first stage (2/22).
CONCLUSION: Hyperthermia is a high-risk event in ELBW infants and methods of cooling a high and prolonged temperature must be reviewed.

Entities:  

Keywords:  Neonatal hypothermia,; Neonatal incubator,; Neonatal mortality,; Tropical hyperthermia

Mesh:

Year:  2015        PMID: 25936414     DOI: 10.1179/2046905515Y.0000000030

Source DB:  PubMed          Journal:  Paediatr Int Child Health        ISSN: 2046-9047            Impact factor:   1.990


  4 in total

1.  Safety and effectiveness of a non-electric infant warmer for hypothermia in Rwanda: A cluster-randomized stepped-wedge trial.

Authors:  Josee Uwamariya; Christian Mazimpaka; Leana May; Alphonse Nshimyiryo; Henry A Feldman; Felix Sayinzoga; Sharon Umutesi; Ashok Gadgil; Vi H Rapp; Evrard Nahimana; Anne Hansen
Journal:  EClinicalMedicine       Date:  2021-04-16

2.  Evaluation of a continuous neonatal temperature monitor for low-resource settings: a device feasibility pilot study.

Authors:  Sonia E Sosa Saenz; Mary Kate Hardy; Megan Heenan; Z Maria Oden; Rebecca Richards-Kortum; Queen Dube; Kondwani Kawaza
Journal:  BMJ Paediatr Open       Date:  2020-05-07

3.  Necessity of early and continuous monitoring for possible infectious complications in children undergoing therapeutic hypothermia.

Authors:  Jennifer B Brandt; Sabine Steiner; Gerald Schlager; Kambis Sadeghi; Regina Vargha; Johann Golej; Michael Hermon
Journal:  Acta Paediatr       Date:  2020-08-12       Impact factor: 2.299

4.  A Low-Cost, Easy-to-Assemble Device to Prevent Infant Hyperthermia under Conditions of High Thermal Stress.

Authors:  Ramon Farré; Miguel A Rodríguez-Lázaro; Anh Tuan Dinh-Xuan; Martí Pons-Odena; Daniel Navajas; David Gozal
Journal:  Int J Environ Res Public Health       Date:  2021-12-19       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.